Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
TTNP Stock Summary
In the News
Which Industries Are Penny Stocks Investors Watching Right Now
Use these tips for finding penny stocks in different industries in 2022 The post Which Industries Are Penny Stocks Investors Watching Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
What to Know About Buying Penny Stocks on July 8th
Here's what you need to know about trading penny stocks on July 8th The post What to Know About Buying Penny Stocks on July 8th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Penny Stocks To Watch: Why KRKR, RMED, TYME, TTNP & ENDP Stock Are Moving
Penny stocks to watch with news The post Penny Stocks To Watch: Why KRKR, RMED, TYME, TTNP & ENDP Stock Are Moving appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Titan Pharmaceuticals Raises $5.5M Via Equity
Titan Pharmaceuticals Inc TTNP has announced a private placement of 3.37 million shares and 1.29 million pre-funded warrants. Thousands of new traders are learning the ins and outs on how to find profitable trades every day with Benzinga Trading School.
Titan Announces Positive Results from the First Studies of TP-2021 Implant in an Established Animal Model of Chronic Pruritus
SOUTH SAN FRANCISCO, Calif., June 23, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that the in vivo study of its human kappa-opioid receptor agonist ("TP-2021," formerly JT-09) ProNeura®-based implant in an established 5'-guanidinonaltrindole (5'-GNTI) itch-induced mouse model, has demonstrated the potential to provide extended efficacy and durability in the treatment of moderate-to-severe chronic pruritus (itch).
Titan Pharmaceuticals Announces Filing Of 2020 Annual Report On Form 10-K
SOUTH SAN FRANCISCO, Calif., March 31, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) announced today that it has filed its annual report on Form 10-K for the fiscal year ended December 31, 2020 with the Securities and Exchange Commission ("SEC").
TTNP Stock Price Increases Over 15% Pre-Market: Why It Happened
The stock price of Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) is trading at over 15% pre-market. This is why it happened.
Positive Early Study Results Help Pave Wave for Titan Pharmaceuticals to Move Forward with its JT-09 ProNeura® Development Program
SOUTH SAN FRANCISCO, Calif., Feb. 1, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that studies of its kappa opioid agonist peptide, JT-09, has demonstrated high potency and specificity for the human kappa-opioid receptor ("KOR"). JT-09 is being developed...
Titan Pharmaceuticals Announces Pricing of $9.7 Million Registered Direct Offering
SOUTH SAN FRANCISCO, Calif., Jan. 15, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced it has entered into a securities purchase agreement with certain accredited institutional investors to purchase approximately $9.7 million of its common stock in a...
Titan Pharmaceuticals Announces Reverse Stock Split
SOUTH SAN FRANCISCO, Calif., Nov. 30, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that its Board of Directors has approved a 1-for-30 reverse stock split of the Company's common stock, which will be effective at 5:00 p.m....
TTNP Financial details
TTNP Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 31.18 | 4.71 | 1.28 | 0.16 | 0 | |
Net income per share | -47.59 | -21 | -5.49 | -0.83 | -0.76 | |
Operating cash flow per share | -44.47 | -20.16 | -4.56 | -0.81 | -0.61 | |
Free cash flow per share | -46.66 | -20.5 | -4.7 | -0.81 | -0.61 | |
Cash per share | 49.02 | 6.82 | 1.43 | 0.62 | 0.22 | |
Book value per share | 36.03 | 1.87 | 0.94 | 0.53 | 0.1 | |
Tangible book value per share | 36.03 | 1.87 | 0.94 | 0.53 | 0.1 | |
Share holders equity per share | 36.03 | 1.87 | 0.94 | 0.53 | 0.1 | |
Interest debt per share | 18.08 | 4.54 | 0.42 | 0.03 | 0.01 | |
Market cap | 150.16M | 87.32M | 248.26M | 198.49M | 209.57M | |
Enterprise value | 145.18M | 86.54M | 243.66M | 192.75M | 206.82M | |
P/E ratio | -16.64 | -5.43 | -11.98 | -24.46 | -20.59 | |
Price to sales ratio | 25.4 | 24.18 | 51.32 | 130.07 | 3.49K | |
POCF ratio | -17.81 | -5.65 | -14.43 | -25.13 | -25.61 | |
PFCF ratio | -16.97 | -5.56 | -13.99 | -25.06 | -25.61 | |
P/B Ratio | 21.98 | 60.94 | 70.29 | 38.63 | 153.76 | |
PTB ratio | 21.98 | 60.94 | 70.29 | 38.63 | 153.76 | |
EV to sales | 24.56 | 23.97 | 50.36 | 126.31 | 3.45K | |
Enterprise value over EBITDA | -18.11 | -4.83 | -45.61 | -19.68 | -20.6 | |
EV to operating cash flow | -17.22 | -5.6 | -14.16 | -24.4 | -25.27 | |
EV to free cash flow | -16.41 | -5.51 | -13.73 | -24.33 | -25.27 | |
Earnings yield | -0.06 | -0.18 | -0.08 | -0.04 | -0.05 | |
Free cash flow yield | -0.06 | -0.18 | -0.07 | -0.04 | -0.04 | |
Debt to equity | 0.63 | 3.1 | 0.23 | 0.06 | 0.14 | |
Debt to assets | 0.31 | 0.47 | 0.1 | 0.04 | 0.05 | |
Net debt to EBITDA | 0.62 | 0.04 | 0.86 | 0.59 | 0.27 | |
Current ratio | 3.85 | 2.31 | 1.74 | 2.71 | 1.37 | |
Interest coverage | 9.32 | 17.42 | -9.56 | -9.35K | 352.93 | |
Income quality | 0.93 | 0.94 | 0.94 | 0.9 | 0.8 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | -0.03 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 1.5 | 1.2 | 3.27 | 100.57 | |
Research and developement to revenue | 1.27 | 2.01 | 1.22 | 3.73 | 79.3 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.05 | 0.02 | 0.03 | 0 | 0 | |
Capex to revenue | -0.07 | -0.07 | -0.11 | -0.02 | 0 | |
Capex to depreciation | -1.09 | -1.05 | -1.85 | -0.1 | 0 | |
Stock based compensation to revenue | 0.26 | 0.16 | 0 | 1.01 | 16.62 | |
Graham number | 196.42 | 29.73 | 10.76 | 3.15 | 1.32 | |
ROIC | -0.61 | -2.62 | -4.58 | -1.51 | -5.88 | |
Return on tangible assets | -0.64 | -1.69 | -2.56 | -1.02 | -2.51 | |
Graham Net | 21.3 | -2.12 | 0.45 | 0.35 | 0.02 | |
Working capital | 9.85M | 4.71M | 3.11M | 4.56M | 973K | |
Tangible asset value | 6.83M | 1.43M | 3.53M | 5.14M | 1.36M | |
Net current asset value | 6.04M | 219K | 2.77M | 4.37M | 908K | |
Invested capital | 0.63 | 3.1 | 0.23 | 0.06 | 0.14 | |
Average receivables | 950.5K | 1.41M | 938.5K | 498K | 74K | |
Average payables | 1.17M | 1.46M | 1.33M | 1.02M | 745K | |
Average inventory | 631K | 1.13M | 663K | 310.5K | 199.5K | |
Days sales outstanding | 113.37 | 100.37 | 66.69 | 26.79 | 219 | |
Days payables outstanding | 1.04K | 397.02 | 968.95 | 1.46K | 1.29K | |
Days of inventory on hand | 856.19 | 282.82 | 253.64 | 537.41 | 197.4 | |
Receivables turnover | 3.22 | 3.64 | 5.47 | 13.63 | 1.67 | |
Payables turnover | 0.35 | 0.92 | 0.38 | 0.25 | 0.28 | |
Inventory turnover | 0.43 | 1.29 | 1.44 | 0.68 | 1.85 | |
ROE | -1.32 | -11.23 | -5.87 | -1.58 | -7.47 | |
Capex per share | -2.19 | -0.33 | -0.14 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 3.8 | 0.01 | 0 | 0 | |
Net income per share | -0.18 | -191.01 | -0.11 | -0.11 | -0.02 | |
Operating cash flow per share | -0.13 | -117.54 | -0.13 | -0.08 | -0.12 | |
Free cash flow per share | -0.13 | -117.54 | -0.13 | -0.08 | -0.12 | |
Cash per share | 0.3 | 218.62 | 0.08 | 0.01 | 0.54 | |
Book value per share | 0.24 | 101.46 | -0.02 | -0.07 | 0.54 | |
Tangible book value per share | 0.24 | 101.46 | -0.02 | -0.07 | 0.54 | |
Share holders equity per share | 0.24 | 101.46 | -0.02 | -0.07 | 0.54 | |
Interest debt per share | 0.02 | 13.92 | 0.01 | 0.01 | 0.04 | |
Market cap | 315.99M | 209.57K | 249.27M | 187.44M | 141.15M | |
Enterprise value | 311.75M | -2.54M | 248.29M | 187.46M | 133.65M | |
P/E ratio | -30 | -0.02 | -37.7 | -29.55 | -104.4 | |
Price to sales ratio | 79K | 4.11 | 2.54K | 187.44K | 35.29K | |
POCF ratio | -168.71 | -0.13 | -131.26 | -168.56 | -76.92 | |
PFCF ratio | -168.71 | -0.13 | -131.26 | -168.56 | -76.92 | |
P/B Ratio | 89.01 | 0.15 | -798.93 | -181.27 | 17.36 | |
PTB ratio | 89.01 | 0.15 | -798.93 | -181.27 | 17.36 | |
EV to sales | 77.94K | -49.81 | 2.53K | 187.46K | 33.41K | |
Enterprise value over EBITDA | -120.14 | 0.99 | -150.11 | -121.02 | -35.49 | |
EV to operating cash flow | -166.45 | 1.61 | -130.75 | -168.58 | -72.83 | |
EV to free cash flow | -166.45 | 1.61 | -130.75 | -168.58 | -72.83 | |
Earnings yield | -0.01 | -12.24 | -0.01 | -0.01 | 0 | |
Free cash flow yield | -0.01 | -7.53 | -0.01 | -0.01 | -0.01 | |
Debt to equity | 0.06 | 0.14 | -0.51 | -0.12 | 0.07 | |
Debt to assets | 0.03 | 0.05 | 0.07 | 0.16 | 0.06 | |
Net debt to EBITDA | 1.63 | 1.07 | 0.59 | -0.01 | 1.99 | |
Current ratio | 2.19 | 1.37 | 0.73 | 0.27 | 5.3 | |
Interest coverage | -125.86 | 108.79K | 77.14 | 0 | 187.36 | |
Income quality | 0.71 | 0.62 | 1.13 | 0.7 | 5.43 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 451.5 | 25.27 | 12.59 | 1.23K | 410.25 | |
Research and developement to revenue | 233 | 28.29 | 5.72 | 442 | 106 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 135.25 | -1.78 | 2.96 | 264 | 102.75 | |
Graham number | 0.99 | 660.33 | 0.23 | 0.42 | 0.52 | |
ROIC | -0.66 | -1.5 | -418.68 | 2.03 | 0.96 | |
Return on tangible assets | -0.42 | -0.63 | -0.76 | -1.95 | -0.03 | |
Graham Net | 0.14 | 23.97 | -0.09 | -0.11 | 0.49 | |
Working capital | 3.12M | 973K | -662K | -1.35M | 8.03M | |
Tangible asset value | 3.55M | 1.36M | -312K | -1.03M | 8.13M | |
Net current asset value | 3.02M | 908K | -695K | -1.35M | 8.03M | |
Invested capital | 0.06 | 0.14 | -0.51 | -0.12 | 0.07 | |
Average receivables | 75K | 42.5K | 22K | 8.5K | 767.5K | |
Average payables | 627.5K | 753.5K | 631K | 582K | 502K | |
Average inventory | 464.5K | 283K | 106K | 130.5K | 94K | |
Days sales outstanding | 1.1K | 63.53 | 7.35 | 810 | 34.34K | |
Days payables outstanding | 1.52K | 1.39K | 1.19K | 121.56 | 1.36K | |
Days of inventory on hand | 862.5 | 212 | 221.86 | 31.56 | 110 | |
Receivables turnover | 0.08 | 1.42 | 12.25 | 0.11 | 0 | |
Payables turnover | 0.06 | 0.06 | 0.08 | 0.74 | 0.07 | |
Inventory turnover | 0.1 | 0.42 | 0.41 | 2.85 | 0.82 | |
ROE | -0.74 | -1.88 | 5.3 | 1.53 | -0.04 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
TTNP Frequently Asked Questions
What is Titan Pharmaceuticals, Inc. stock symbol ?
Titan Pharmaceuticals, Inc. is a US stock , located in South san francisco of Ca and trading under the symbol TTNP
What is Titan Pharmaceuticals, Inc. stock quote today ?
Titan Pharmaceuticals, Inc. stock price is $6.85 today.
Is Titan Pharmaceuticals, Inc. stock public?
Yes, Titan Pharmaceuticals, Inc. is a publicly traded company.